ORGANOGENESIS HOLDINGS INC
Organogenesis Holdings, Inc. (ORGO) is a commercial-stage regenerative medicine company focused on advanced wound care and surgical biologics. The business markets tissue-based and cellular therapies intended to support healing in chronic wounds, acute surgical settings and orthopaedic applications, generating revenue mainly from product sales and related services. With a market capitalisation of roughly $516 million, ORGO’s progress is driven by product adoption, clinical evidence, reimbursement policies and distribution partnerships. Potential strengths include specialised clinical expertise and an established customer base, while sector risks include regulatory decisions, competitive pressures from larger medtech firms, clinical trial outcomes and intellectual property disputes. As a smaller healthcare company, share-price volatility and liquidity can be higher than for large-caps. This summary is for general educational purposes only and is not personal investment advice; investors should review the company’s filings, recent results and seek independent financial advice to assess suitability.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Organogenesis Holdings stock as it has significant growth potential.
Financial Health
Organogenesis is performing well with solid revenue and profit margins, indicating strong business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ORGO
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial traction
Revenue growth and hospital adoption indicate commercial traction; monitor sales trends and distribution metrics, though performance can vary.
Innovation pipeline
New product development and clinical data can drive long-term value, but trials and approvals carry uncertainty and timing risk.
Reimbursement landscape
Reimbursement and procurement policies shape uptake in healthcare settings; policy shifts can materially affect revenues.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
